Vor Biopharma (NASDAQ:VOR) Posts Earnings Results

Key Points

• Vor Biopharma reported a quarterly loss of $0.80 per share, missing the consensus estimate of a $0.69 loss by $0.11.
• Shares fell $0.39 to $22.98 in Tuesday trading, though the stock remains well above its 52-week low of $6.50 and below its high of $50.20.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $42.25; institutional investors own 97.29% of outstanding shares.

Vor Biopharma (NASDAQ:VOR - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11), Zacks reports.

Vor Biopharma Stock Performance

Shares of VOR traded down $0.39 during trading hours on Tuesday, hitting $22.98. The stock had a trading volume of 77,701 shares, compared to its average volume of 1,068,374. The firm has a 50 day simple moving average of $17.80 and a 200-day simple moving average of $15.84. Vor Biopharma has a 1-year low of $6.50 and a 1-year high of $50.20.

Analyst Ratings Changes

Several equities research analysts have weighed in on VOR shares. Jefferies Financial Group upgraded Vor Biopharma to a "strong-buy" rating in a research note on Thursday, April 30th. Weiss Ratings raised shares of Vor Biopharma from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, June 30th. Wall Street Zen cut Vor Biopharma from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. HC Wainwright reaffirmed a "buy" rating and issued a $31.00 target price on shares of Vor Biopharma in a report on Monday, May 18th. Finally, Wedbush boosted their price target on Vor Biopharma from $15.00 to $18.00 and gave the stock a "neutral" rating in a report on Thursday, May 14th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Vor Biopharma currently has a consensus rating of "Moderate Buy" and an average target price of $42.25.

Hedge Funds Weigh In On Vor Biopharma

A number of large investors have recently modified their holdings of the company. Bank of America Corp DE increased its stake in Vor Biopharma by 679.3% during the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company's stock valued at $232,000 after purchasing an additional 4,144 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Vor Biopharma during the third quarter worth about $230,000. BNP Paribas Financial Markets lifted its position in Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company's stock valued at $296,000 after acquiring an additional 5,058 shares in the last quarter. Bridgeway Capital Management LLC bought a new position in Vor Biopharma in the 3rd quarter valued at about $304,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in Vor Biopharma during the 4th quarter valued at about $134,000. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source